Cytodyn Inc (CYDY)

[stockorus]

Could be, for that indication. I don't recall the details of that trial. It was preliminary and low-powered trial, and for most patients in that phase, the recovery may be natural and so much more difficult to establish that our drug makes a significant difference.

Remember also that LL is expected to make its main impact in the second phase of covid, if the disease progresses beyond the viral phase and into the cytokine storm stage. So even if it is not very effective for mild disease, it could be much more effective for severe/critical.

cd12 was "hypothesis-generating". We have now filtered the 'optimal' indications, trial design, dosage etc. for the Brazil trials based on the knowledge we gained from earlier trials. Things are in the right place and the Brazil trials need to be completed for a final assessment of LL in Covid.